Long-term improvement after combined immunomodulation in early post-H1N1 vaccination narcolepsy

Neurology: Neuroimmunology and NeuroInflammation

Volumn 4, Issue 5, 2017, Pages

  Viste, Rannveig ^a,b,g   Soosai, Joseph ^c   Vikin, Truls ^c,h   Thorsby, Per Medbøe ^e,f   Nilsen, Kristian Bernhard ^f   Knudsen, Stine ^a,d  

^a Norwegian Centre of Expertise for Neurodevelopmental Disorders and Hypersomnias (NevSom)   (Norway)

^b Section for Clinical Neurophysiology   (Norway)

^c Department of Child Neurology ^*  (Norway)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e Hormone Laboratory   (Norway)

^f AKER UNIVERSITY HOSPITAL   (Norway)

^g NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^h UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; INFLUENZA VACCINE; METHYLPREDNISOLONE; OREXIN A;

ALLERGIC ASTHMA; CASE REPORT; CATAPLEXY; CEREBROSPINAL FLUID ANALYSIS; CHILD; CLINICAL ARTICLE; COMBINATION DRUG THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; EPWORTH SLEEPINESS SCALE; FOLLOW UP; HUMAN; HYPNAGOGIC HALLUCINATION; IMMUNOMODULATION; INFLUENZA A (H1N1); INFLUENZA VACCINATION; MALE; MEDICAL HISTORY; MUSCLE WEAKNESS; NARCOLEPSY; NARCOLEPSY TYPE 1; NIGHT SLEEP; PANDEMIC INFLUENZA; PARASOMNIA; PRESCHOOL CHILD; PRIORITY JOURNAL; SHORT SURVEY; SLEEP WALKING; SOMNOLENCE; VACCINATION REACTION;

EID: 85029083851     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000389     Document Type: Short Survey

References (7)

1. Knudsen S, Mikkelsen JD, Gammeltoft S, Jennum P. Intravenous immunoglobulin treatment and screening for hypocretin neuron-specific autoantibodies in recent onset childhood narcolepsy with cataplexy. Neuropediatrics 2010; 41: 217-222.
2. Knudsen S, Biering-Sorensen B, Kornum BR, et al. Early IVIg treatment has no effect on post-H1N1 narcolepsy phenotype or hypocretin deficiency. Neurology 2012; 79: 102-103.
3. Faraco J, Lin L, Kornum BR, et al. ImmunoChip study implicates antigen presentation to T cells in narcolepsy. PLoS Genet 2013; 9: e1003270.
4. Mignot E, Lin L, Rogers W, et al. Complex HLA-DR and-DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet 2001; 68: 686-699.
5. Kornum BR, Kawashima M, Faraco J, et al. Common variants in P2RY11 are associated with narcolepsy. Nat Genet 2011; 43: 66-71.
6. Savvidou A, Knudsen S, Olsson-Engman M, Gammeltoft S, Jennum P, Palm L. Hypocretin deficiency develops during onset of human narcolepsy with cataplexy. Sleep 2013; 36: 147-148.
7. Boehmer LN, Wu MF, John J, Siegel JM. Treatment with immunosuppressive and anti-inflammatory agents delays onset of canine genetic narcolepsy and reduces symptom severity. Exp Neurol 2004; 188: 292-299.